Data suggest that alanine may facilitate the intestinal absorption of fructose in patients with DFI and thereby may decrease GI symptoms. We hypothesize that the ingestion of supplemental L-alanine along with mixed meals or snacks that contain foods with free fructose or high fructose content will decrease GI symptoms in subjects with dietary fructose intolerance by facilitating intestinal absorption of fructose. Aim: To investigate the effects of co- administration of equi-molar doses of L-alanine or placebo on the occurrence of GI symptoms in subjects with dietary fructose intolerance, in a randomized, double blind, cross over study. Methods: We propose to investigate the effects of co-administration of equi-molar doses of L-alanine or placebo on the occurrence of GI symptoms in 70 subjects with dietary fructose intolerance, in a randomized, double blind, cross over study. Data Analysis: The primary outcome measure will be a comparison of baseline breath sample values and study visit breath sample values. Additionally, we will assess subject-reported occurence and severity of nine gastrointestinal symptoms during the test on a visual analog scale (VAS). Expected Results: We anticipate that dietary fructose intolerance (DFI) symptoms will improve with ingestion of supplemental L-alanine (along with foods containing free fructose or high fructose content). We additionally expect treatment of DFI with administration of L-alanine powder to be more practical than co-ingestion of alanine-rich foods, and more convenient for patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
15
Subjects will consume l-alanine prior to eating fructose-containing foods.
Subjects will consume the placebo prior to eating fructose-containing foods.
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
GI symptom score
Change in GI symptom score with alanine \& placebo, when compared to the baseline
Time frame: 4 weeks
Fructose consumption
Estimated daily consumption of fructose during the alanine \& placebo phases, when compared to baseline using prospective food diaries
Time frame: 4 weeks
Breath hydrogen and methane
Changes in Breath hydrogen and/or methane values with Alanine and Placebo when compared with baseline
Time frame: 4 weeks
Quality of life (SF-12)
Changes in SF-12 scores between baseline and after alanine and placebo
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.